Research programme: colorectal cancer therapies - ChemRegen
Latest Information Update: 01 Aug 2016
At a glance
- Originator ChemRegen
- Class Antineoplastics; Small molecules
- Mechanism of Action Signal transduction pathway modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer
Most Recent Events
- 01 Aug 2016 Early research in Colorectal cancer in USA (unspecified route)